| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCYC | Ordinary Shares | Sale | -$19.7K | -588 | -0.03% | $33.50 | 1.88M | Jul 13, 2021 | By SV Life Sciences Fund V, L.P. | F1, F2 |
| transaction | BCYC | Ordinary Shares | Sale | -$1.48M | -43.4K | -2.31% | $34.01 | 1.83M | Jul 14, 2021 | By SV Life Sciences Fund V, L.P. | F1, F2 |
| transaction | BCYC | Ordinary Shares | Sale | -$402 | -12 | -0.03% | $33.50 | 39.6K | Jul 13, 2021 | By SV Life Sciences Fund V Strategic Partners, L.P. | F3, F4 |
| transaction | BCYC | Ordinary Shares | Sale | -$31.2K | -917 | -2.31% | $34.01 | 38.7K | Jul 14, 2021 | By SV Life Sciences Fund V Strategic Partners, L.P. | F3, F4 |
Kate Bingham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. |
| F2 | These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. |
| F3 | These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. |
| F4 | These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. |
The original Form 4 filed on July 15, 2021 is amended by this Form 4 amendment to reflect Ms. Bingham's resignation from the Board of Directors effective as of the Annual Meeting held on June 28, 2021. As a result of her resignation, Ms. Bingham is no longer subject to Section 16 reporting requirements.